Public trial registry of the CCC-Munich

Trial IMMULAB

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial
World
Trial acronym
:
IMMULAB
World
Full title
:

IMMULAB – Eine Phase-II-Studie zur Immuntherapie mit Pembrolizumab in Kombination mit lokaler Ablation für Patienten mit hepatozellulärem Karzinom (HCC) im Frühstadium

World
Description
:

This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity of peri-interventional treatment with the anti-PD1 antibody pembrolizumab in HCC patients who are candidates for local ablation via either radiofrequency ablation (RFA) or microwave ablation (MWA).

World
EudraCT number
:
World
NCT number
:
World
Responsible organization
:
Medizinische Klinik II, Telefon: 089440072791
Indications
Classification Code Description
ICD-10-GM C22.0 Leberzellkarzinom
- Livertumor
Trial design
World
Trial type
:
Interventional
World
Blinding type
:
Open
World
Phase
:
II
Status
World
Status
:
Recruitment finished
Votes
World
Institutional review board - vote
:
Unknown
Initiiation & lock
World
Date of lock (planned / actual)
:
2024-06-30 / Unknown
Documents Public
Document Language Version Uploaded/Updated at
World Trial Protocol de 9.0 2021-02-01 11:24:41 UTC
Participants
Function Prename Surname Organization
World Principal Investigator Enrico Toni Keine Organisationseinheit angegeben Magnifier
World Responsible contact ALEXANDER PHILIPP Keine Organisationseinheit angegeben Magnifier